BR112022006283A2 - Conjugados de anticorpos específicos para amatoxina de linfócitos b, composição farmacêutica e uso - Google Patents

Conjugados de anticorpos específicos para amatoxina de linfócitos b, composição farmacêutica e uso

Info

Publication number
BR112022006283A2
BR112022006283A2 BR112022006283A BR112022006283A BR112022006283A2 BR 112022006283 A2 BR112022006283 A2 BR 112022006283A2 BR 112022006283 A BR112022006283 A BR 112022006283A BR 112022006283 A BR112022006283 A BR 112022006283A BR 112022006283 A2 BR112022006283 A2 BR 112022006283A2
Authority
BR
Brazil
Prior art keywords
amatoxin
pharmaceutical composition
lymphocyte
specific antibody
antibody conjugates
Prior art date
Application number
BR112022006283A
Other languages
English (en)
Inventor
Hechler Torsten
Kulke Michael
Muller Christoph
Pahl Andreas
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of BR112022006283A2 publication Critical patent/BR112022006283A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

conjugados de anticorpos específicos para amatoxina de linfócitos b, composição farmacêutica e uso. o presente pedido refere-se a um conjugado compreendendo uma amatoxina, uma fração de ligação ao alvo em que o alvo é cd20, ou seja, uma fração de ligação a cd20 e, opcionalmente, um ligante que liga a referida amatoxina e a referida fração de ligação a cd20. a invenção refere-se ainda à síntese do referido conjugado. além disso, a invenção refere-se a uma composição farmacêutica compreendendo tal conjugado, particularmente para uso no tratamento de doenças e/ou malignidades associadas a células b e/ou linfoma.
BR112022006283A 2019-10-15 2020-10-15 Conjugados de anticorpos específicos para amatoxina de linfócitos b, composição farmacêutica e uso BR112022006283A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203400 2019-10-15
PCT/EP2020/078979 WO2021074261A1 (en) 2019-10-15 2020-10-15 B-lymphocyte specific amatoxin antibody conjugates

Publications (1)

Publication Number Publication Date
BR112022006283A2 true BR112022006283A2 (pt) 2022-06-21

Family

ID=68281092

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006283A BR112022006283A2 (pt) 2019-10-15 2020-10-15 Conjugados de anticorpos específicos para amatoxina de linfócitos b, composição farmacêutica e uso

Country Status (12)

Country Link
EP (1) EP4045091A1 (pt)
JP (1) JP2022552349A (pt)
KR (1) KR20220082846A (pt)
CN (1) CN114845737A (pt)
AR (1) AR120218A1 (pt)
AU (1) AU2020367014A1 (pt)
BR (1) BR112022006283A2 (pt)
CA (1) CA3151578A1 (pt)
CO (1) CO2022004606A2 (pt)
IL (1) IL291581A (pt)
MX (1) MX2022004416A (pt)
WO (1) WO2021074261A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3192529T1 (sl) * 2009-04-08 2020-07-31 Faulstich, Heinz Dr. Z amatoksinom ojačane vezne komponente terapevtske celične površine, zasnovane za zdravljenje tumorjev
ES2402254T3 (es) * 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
WO2016071856A1 (en) * 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
JP6863900B2 (ja) * 2015-03-09 2021-04-21 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規アマトキシン−抗体コンジュゲート
US11413353B2 (en) * 2015-11-25 2022-08-16 Legochem Biosciences, Inc. Conjugates comprising self-immolative groups and methods related thereto
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
BR112018071465A2 (pt) * 2016-04-20 2019-02-05 Hangzhou Dac Biotech Co Ltd derivados de toxinas de amanita e sua conjugação a uma molécula de ligação celular
MX2019007604A (es) * 2016-12-23 2019-08-16 Heidelberg Pharma Res Gmbh Novedoso conjugado de amanitina.
CA3076289A1 (en) * 2017-09-22 2019-03-28 Heidelberg Pharma Research Gmbh Psma-targeting amanitin conjugates
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells

Also Published As

Publication number Publication date
KR20220082846A (ko) 2022-06-17
MX2022004416A (es) 2022-05-24
CO2022004606A2 (es) 2022-07-08
AR120218A1 (es) 2022-02-02
AU2020367014A1 (en) 2022-04-14
EP4045091A1 (en) 2022-08-24
IL291581A (en) 2022-05-01
CA3151578A1 (en) 2021-04-22
CN114845737A (zh) 2022-08-02
WO2021074261A1 (en) 2021-04-22
JP2022552349A (ja) 2022-12-15

Similar Documents

Publication Publication Date Title
CO2018009533A2 (es) Conjugados de amanitina
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
BR112017002080A2 (pt) ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica?
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112021023229A2 (pt) Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
AR078470A1 (es) Anticuerpos que se unen especificamente al receptor epha2
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
BRPI0608815A8 (pt) Composições de anticorpo anti-ctla-4
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
UY31466A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
BR112018068461A2 (pt) conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
BR112021015109A2 (pt) Conjugado de fármaco-ligante duplo e uso do mesmo
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
BR112022019532A2 (pt) Conjugados de neodegrader
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
BR112021009673A2 (pt) Derivados de bis-octa-hidrofenantreno carboxamida e conjugados de proteínas dos mesmos para uso como agonistas de lxr
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
BR112023004415A2 (pt) Moléculas terapêuticas de ligação a b7-h4
BR112018000909A2 (pt) imunoconjugados de il22